Nonpeptide arginine vasopressin antagonists for both V(1A) and V2 receptors: Synthesis and pharmacological properties of 4'-[5-(substituted methylidene)-2,3,4,5-tetrahydro-1H-1-benzoazepine-1-carbonyl]benzanilide and 4'-[5-(substituted methyl)-2,3-dihydro-1H-1-benzoazepine-1- carbonyl]benzanilide derivatives

Chemical and Pharmaceutical Bulletin

Volumn 47, Issue 3, 1999, Pages 329-339

  Matsuhisa, Akira ^a   Kikuchi, Kazumi ^a   Sakamoto, Kenichiro ^a   Yatsu, Takeyuki ^a   Tanaka, Akihiro ^a  

^a ASTELLAS PHARMA INC   (Japan)

Author keywords

Antidiuretic hormone; Arginine vasopressin antagonist; Benzanilide; Benzoazepine; Congestive heart failure

Indexed keywords

ARGIPRESSIN RECEPTOR; N METHYL[1 [4 (2 METHYLBENZOYLAMINO)BENZOYL] 2,3,4,5 TETRAHYDRO 1H 1 BENZOAZEPIN 5 YLIDENE]ACETAMIDE; N METHYL[1 [4 [2 (4 METHYLPHENYL)BENZOYLAMINO]BENZOYL] 2,3,4,5 TETRAHYDRO 1H 1 BENZOAZEPIN 5 YLIDENE]ACETAMIDE; UNCLASSIFIED DRUG; VASOPRESSIN RECEPTOR ANTAGONIST; VASOPRESSIN V1 RECEPTOR; VASOPRESSIN V2 RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG RECEPTOR BINDING; DRUG SYNTHESIS; EDEMA; HYPERTENSION; HYPONATREMIA; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY DISEASE; NONHUMAN; RABBIT; RAT;

EID: 0032950587     PISSN: 00092363     EISSN: None     Source Type: Journal    
DOI: 10.1248/cpb.47.329     Document Type: Article

References (14)

1. Michel R. H., Kirk C. J., Billah M. M., Biochem. Soc. Trans., 7, 861-865 (1979).
2. Jard S., Kidney Int., Supp., 26, 38-42 (1988).
3. Yatsu T., Tomura Y., Tahara A., Wada K., Tsukada J., Uchida W., Tanaka A., Takenaka T., Eur. J. Pharmacol, 321, 225-230 (1997).
4. Manning M., Sawyer W. H., J. Lab. Clin. Med., 114, 617-632 (1989).
5. Creager M. A., Facon D. P., Cutler S. S., Kohlmann O., Ryan T. J., Gavras H., J. Am. Coll. Cardiol., 7, 758-765 (1986).
6. Goldsmith S.R., Francis G.S., Cowly A.W., Jr., Goldenberg I. F., Cohn J. N., J. Am. Coll. Cardiol., 8, 779-783 (1986).
7. Lee W. H., Packer M., Circuration, 73, 257-267 (1986).
8. Mulinari R. A., Gavras I., Wang Y. X., Franco R., Gavras H., Circulation, 81, 308-311 (1990).
9. Naitoh M., Suzuki H., Murakami M., Matsumoto A., Arakawa K., Ichihara A., Nakamoto H., Oka K., Yamamura Y., Saruta T., Am. J. Physiol., 267, H2245-H2254 (1994).
10. Tahara A., Tomura Y., Wada K., Kusayama T., Tsukada J., Takanashi M., Yatsu T., Uchida W., Tanaka A., J. Pharmacol Exp. Ther., 282, 301-308 (1997).
11. Matsuhisa A., Koshio H., Sakamoto K., Taniguchi N., Yatsu T., Tanaka A., Chem. Pharm. Bull., 46, 1566-1579 (1998).
12. Ogawa H., Yamashita H., Kondo K., Yamamura Y., Miyamoto H., Kan K., Kitano K., Tanaka M., Nakaya K., Nakamura S., Mori T., Tominaga M., Yabuuchi Y., J. Med. Chem., 39, 3547-3555 (1996).
13. 2 receptor binding affinity potential of some compounds for rat kidney and for rabbit kidney in our investigation (data not shown).
14. Experimental method described in reference (11).